Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rosnilimab (ANB030) for moderate-to-severe alopecia areata; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Rosnilimab (Rosnilimab)

Snippet

Sponsor: AnaptysBio, Inc. | Conditions: Alopecia Areata | Phase 2 | Status: UNKNOWN